Midphase data are arriving thick and fast at Imbria Pharmaceuticals. Days after sharing positive top-line data in one indication, the cardiometabolic biotech has reported a phase 2 trial of the same candidate in a different setting has met its primary endpoint.
Imbria touts PhII success in hypertrophic cardiomyopathy
Imbria Pharmaceuticals’ heart failure medicine met the safety and tolerability goals in a phase 2 trial while also improving results on a cardiopulmonary exercise test, with patients reporting other improvements in their conditions as well.
BOSTON--(BUSINESS WIRE)--Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced the appointment of biopharmaceutical industry veteran John Young to its board of directors.
BOSTON--(BUSINESS WIRE)--Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today announced that Anne Prener, president and chief executive officer, Jai Patel, chief medical officer, and Komal Joshi, chief financial officer will participate in SVB Leerink's Biopharma Private Company Connect, taking place virtually on March 29-31, 2022.
Imbria Announces Initiation of Enrollment in IMPROVE-HCM
Imbria Pharmaceuticals, a clinical stage biopharmaceutical company developing novel therapies designed to enhance cellular energetics for the treatment of major forms of heart disease and specific inborn errors of metabolism, today announced that the first 10 (ten) patients were dosed in the IMPROVE-DiCE Phase 2a, open-label study of IMB-1018972 (IMB-101) in patients with Type 2 diabetes at risk of diabetic cardiomyopathy.